Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma

Journal article


Authors/Editors


Research Areas

No matching items found.


Publication Details

Author list: Martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, Valencia ME, Alegre M, Podzamczer D, Gonzalez-Lahoz J
Publisher: Lippincott, Williams & Wilkins
Publication year: 2004
Volume number: 18
Issue number: 12
Start page: 1737
End page: 1740
Number of pages: 4
ISSN: 0269-9370
Languages: English-Great Britain (EN-GB)


Abstract

Twenty-eight HIV patients either naive or failing highly active antiretroviral therapy (HAART) with moderate-advanced Kaposi's sarcoma (KS) were randomly chosen to initiate a new HAART regimen plus pegylated liposomal doxorubicin (PLD) or the new HAART regimen alone. After 48 weeks, better response rates were observed in the HAART plus PLD group (76% versus 20%). In HIV-infected patients with moderate-advanced KS, HAART alone may not be enough for KS response.


Keywords

No matching items found.


Documents

No matching items found.

Last updated on 2019-23-08 at 11:15